Sign up USA
Proactive Investors - Run By Investors For Investors

Intuitive Surgical shares gain as profit beats estimates on da Vinci device sales

The company said it shipped 185 robotic surgery devices in the quarter
The surgeon console and patient cart which are part of the da vinci system
The stock of the maker of robotic surgical systems rose 7.8%

Shares of Intuitive Surgical Inc. (NASDAQ:ISRG) gained after first-quarter earnings beat analysts’ estimates,  fueled by sales of its da Vinci Xi robotic surgery device.

The stock jumped 7.8% to US$469.41 at 12:06 p.m.

Intuitive Surgical yesterday said after the market close that net income rose to US$288mln, or US$2.44 per share on an adjusted basis, from US$180.8mln, or US$1.57 a share, a year earlier. Analysts were expecting earnings per share of US$1.99.

The company also posted $848mln in revenue, a 25% increase from the year-ago quarter and beating the Wall Street consensus estimate of $777mln.

The Sunnyvale, California-based company said it shipped 185 da Vinci systems in the first three months of 2018, about 39% more than a year earlier. Intuitive got the first-of-its-kind clearance for its robotic surgical system from the US Food and Drug Administration in 2000.

Surgeons who tout the tech say it’s given them a far clearer view of what’s happening inside the body and greater control over their instruments.

The da Vinci device, previously only cleared for prostatectomy and nephrectomy in Japan, is now approved for 12 other procedures within the specialties of general surgery, gynecology and cardiothoracic surgery. They were granted "national reimbursement" status, which means that the Japanese healthcare system provides economic incentives to convert procedures in these categories to robotics.

View full ISRG profile View Profile

Intuitive Surgical Timeline

Related Articles

profit meter
April 02 2018
Having secured US$6.9mln of new investment, the company is now primed for growth
scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use